Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (18707)	4/6/1998 11:02:00 PM
From: Bryce Elkins	Read Replies (11) \| Respond to of 32384

Henry - First thanks for all your informative news about Ligand; I've leaned much about the research compounds and especially Targretin from your posts. For me, the Tamoxifin news just brings to the fore the progress of research in this area to average investors, like myself, and thus heightens the possibility of added interest in Ligand shares to go with their pipeline of research drugs. I doubled my holdings today in LGND. Ble